ClinicalTrials.gg
Active, not recruitingNCT07223281Updated Nov 10, 2025

Real-World Effectiveness of Amniotic Membrane Allografts Versus Standard Wound Care in DFU, VLU, and PU

An observational study in Diabetic Foot Ulcer (DFU), Venous Leg Ulcers (VLUs) and Pressure Ulcers, Bedsores, Decubitus Ulcer, sponsored by Legacy Medical Consultants. Active, not recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-10.

Sponsored by Legacy Medical Consultants · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
2,400
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 381 studies in Diabetic Foot with a site in United States — 66 open to participants now, 84 under way, 3 of them phase 3. Diabetic Foot · United States.

Planned enrollment
10th of 58
2,400 · median 138
Started
2025
with 29 others
Observational
58 of 381
11 open now
Primary completion
2025-11
later than 13 of 83 live
Registered
364th of 381
by date

Among the 381 studies in Diabetic Foot with a site in United States, this one is the 10th largest by planned enrollment of the 58 observational ones that give a count, is one of 30 that started in 2025, is one of 58 observational ones, reaches primary completion later than 13 of the 83 other live ones, and was the 364th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

66 of the 381 studies in Diabetic Foot with a site in United States are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies in Diabetic Foot with a site in United States, or all of them as a file.
02

Study summary

This observational study will evaluate the real-world effectiveness of four amniotic membrane-based products (Zenith™, Orion™, SurGraft FT™, Complete ACA™) in addition to standard care, compared with standard care alone. The study will use complete electronic health records (EHR) from multiple wound care centers across the United States (2022-2025) to generate study data for product-treated and propensity score-matched standard care cohorts for each product-indication combination. The overall study comprises 12 parallel sub-studies (one for each product-wound type combination), each aiming to answer whether adding the product improves healing outcomes versus standard care alone in that indication. The primary endpoint is the proportion of wounds achieving complete closure within 12 weeks, with subgroup analyses by wound severity measures, age groups, and number of product applications. Secondary outcomes are time-to-healing, early wound improvement (≥50% reduction in wound area by 4 weeks), wound-related complications, and subgroup analyses.

03

Conditions studied

  • Diabetic Foot Ulcer (DFU)
  • Venous Leg Ulcers (VLUs)
  • Pressure Ulcers, Bedsores, Decubitus Ulcer

Keywords

  • real world evidence
  • wound healing
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with DFU, VLU, or PU

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥18; DFU/VLU/PU; sufficient observable timeline

Exclusion criteria

Exclusion Criteria:

  • Use of other advanced wound products, atypical ulcer etiology (e.g., , vasculitis); insufficient follow-up
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
2,400 participants (estimated)
Patient registry
No

Groups and cohorts

  • Zenith™ + Standard care for DFU

    Patients who received Zenith™ plus standard care for their DFU

  • Orion™ + Standard care for DFU

    Patients who received Orion™ plus standard care for their DFU

  • SurGraft FT™ + Standard care for DFU

    Patients who received SurGraft FT™ plus standard care for their DFU

  • Complete ACA™ + Standard care for DFU

    Patients who received Complete ACA™ plus standard care for their DFU

  • Standard care alone for DFU

    Patients who received standard care only for their DFU

  • Zenith™ + Standard care for VLU

    Patients who received Zenith™ plus standard care for their VLU

  • Orion™ + Standard care for VLU

    Patients who received Orion™ plus standard care for their VLU

  • SurGraft FT™ + Standard care for VLU

    Patients who received SurGraft FT™ plus standard care for their VLU

  • Complete ACA™ + Standard care for VLU

    Patients who received Complete ACA™ plus standard care for their VLU

  • Standard care alone for VLU

    Patients who received standard care only for their VLU

  • Zenith™ + Standard care for PU

    Patients who received Zenith™ plus standard care for their PU

  • Orion™ + Standard care for PU

    Patients who received Orion™ plus standard care for their PU

  • SurGraft FT™ + Standard care for PU

    Patients who received SurGraft FT™ plus standard care for their PU

  • Complete ACA™ + Standard care for PU

    Patients who received Complete ACA™ plus standard care for their PU

  • Standard care alone for PU

    Patients who received standard care only for their PU

06

What researchers measure

Primary outcomes

  1. Complete wound closure at 12 Weeks

    Proportion of index wounds with 100% epithelialization, no drainage or dressings; confirmation on ≥1 follow-up within 60 days

    Time frame: From index visit to 12 weeks post-index

Secondary outcomes

  1. Time to complete wound closure

    Time from the index visit to primary complete wound closure for wounds that heal during the study period

    Time frame: From index visit up to 24 months post-index

  2. ≥50% wound area reduction at 4 weeks

    Proportion of patients whose wounds close greater than 50% within 4 weeks from the index visit

    Time frame: From index visit to 4 weeks post-index

  3. Wound-related complications

    Wound-related complications including infection requiring treatment, hospitalization, ED visits, and major or minor amputation

    Time frame: From index visit up to 24 months post-index

07

Study locations

4 sites
  • Colorado Foot and Ankle
    Colorado Springs, Colorado 80903, United States
  • Podiatric Surgical Specialists
    Clinton Township, Michigan 48038, United States
  • Advanced Wound Therapy
    Tulsa, Oklahoma 74137, United States
  • Comprehensive Occupational Medicine
    Nitro, West Virginia 25143, United States
08

References and documents

Publications

  • Kahoun, J., Gorenstein, S., & Gillette, B. (2025). Real-World Performance of Amniotic Membrane Allografts for Chronic Wounds: Multi-Site Results from a Retrospective EHR Study. https://doi.org/10.5281/zenodo.17504472
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Nov 2025, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2025
First posted
Oct 31, 2025
StartActual
Sep 25, 2025
Primary completionEst.
Nov 2025
CompletionEst.
Dec 2025
Last update
Nov 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07223281
Lead sponsor
Legacy Medical Consultants
Responsible party
Sponsor
First posted
Oct 31, 2025
Start date
Sep 25, 2025
Primary completion
Nov 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Nov 10, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion